Skip to main content

Research Repository

Advanced Search

Antimalarial pharmacology and therapeutics of atovaquone

Antimalarial pharmacology and therapeutics of atovaquone Thumbnail


Abstract

Atovaquone is used as a fixed-dose combination with proguanil (Malarone) for treating children and adults with uncomplicated malaria or as chemoprophylaxis for preventing malaria in travellers. Indeed, in the USA, between 2009 and 2011, Malarone prescriptions accounted for 70% of all antimalarial pre-travel prescriptions. In 2013 the patent for Malarone will expire, potentially resulting in a wave of low-cost generics. Furthermore, the malaria scientific community has a number of antimalarial quinolones with a related pharmacophore to atovaquone at various stages of pre-clinical development. With this in mind, it is timely here to review the current knowledge of atovaquone, with the purpose of aiding the decision making of clinicians and drug developers involved in the future use of atovaquone generics or atovaquone derivatives.

Citation

(2013). Antimalarial pharmacology and therapeutics of atovaquone. Journal of Antimicrobial Chemotherapy, 977-985. https://doi.org/10.1093/jac/dks504

Acceptance Date Jan 4, 2013
Publication Date Jan 4, 2013
Journal Journal of Antimicrobial Chemotherapy
Print ISSN 0305-7453
Publisher Oxford University Press
Pages 977-985
DOI https://doi.org/10.1093/jac/dks504
Keywords malaria, drug development, mechanism of action, resistance, drug interactions
Publisher URL http://dx.doi.org/10.1093/jac/dks504

Files






Downloadable Citations